Skip to main content

Additional Advances in Myelofibrosis Research and Clinical Trials With John Mascarenhas, MD

Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians.  

Continue reading

Staying Up to Date on Management of Tumor Lysis Syndrome With Amy Goodrich, MSN, RN, CRNP

Tumor lysis syndrome (TLS) is a rare, potentially life-threatening oncologic emergency typically associated with chemotherapy-induced tumor cell death in which potassium, phosphate, and nucleic acids are released into the bloodstream. The most effective management strategy is prevention; however, despite appropriate prophylactic measures, approximately 3% to 5% of high-risk patients receiving chemotherapy are affected.

In this interview, Amy Goodrich, MSN, RN, CRNP, a Nurse Practitioner and Research Nursing Manager at the Johns Hopkins Kimmel Cancer Center, discusses a recent educational activity she co-led, Best Practices in the Management of Tumor Lysis Syndrome Associated With Emerging Cancer Therapies

Continue reading

Oncology Showdown Activity Tackles Proficiency in Treatment of Advanced Non-Hodgkin Lymphoma

An educational live and enduring activity provided by i3 Health has demonstrated significant learning outcomes for treatment of patients with advanced non-Hodgkin lymphoma (NHL). The live activity, which was presented virtually at the 4th Annual GLAONS Oncology Care Summit, used a competitive, team-based "game show" format to explore the latest strategies and expert perspectives in treatment of patients with advanced NHL, including subtypes of follicular lymphoma (FL) and chronic lymphocytic leu...

Continue reading

Supporting Educational Needs in Treatment of Advanced Non–Small Cell Lung Cancer

An educational enduring activity provided by i3 Health demonstrated significant learning outcomes in the selection of treatment for patients with anaplastic lymphoma kinase (ALK)–positive advanced non–small cell lung cancer (NSCLC). This activity was created to advise clinicians on the development of individualized treatment plans based on the best available evidence and emerging guideline recommendations. Lung cancer is the second most common cancer in the United States, and the first most dead...

Continue reading

Managing Treatment-Related Adverse Effects of Multiple Myeloma: Beth Faiman, PhD, MSN, APN-BC, AOCN®, FAAN

Multiple myeloma is a cancer of the bone marrow plasma cells that causes the overproduction of monoclonal immunoglobulins, which can lead to organ damage. In this excerpt of the transcript from her nursing continuing professional development (NCPD)-approved activity, Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care, Beth Faiman, PhD, MSN, APN-BC, AOCN®, FAAN, a nurse practitioner at the Cleveland Clinic Taussig Cancer Institute, discusses strateg...

Continue reading

Learning Needs in Immune Thrombocytopenia

Immune thrombocytopenia (ITP) is a heterogeneous disorder that involves a shortage of platelets, or thrombocytes, and can result in excessive bruising or bleeding. Diagnosis and treatment are challenging due to the lack of specific diagnostic criteria and the widely varying clinical features: some patients remain asymptomatic, whereas others experience troublesome bruising or even life-threatening intracranial hemorrhage. The optimal management of ITP necessitates an individualized approach that...

Continue reading

Knowledge Gaps Revealed in Waldenström Macroglobulinemia

Waldenström macroglobulinemia is a rare lymphoproliferative disorder, with an estimated 1,500 new cases reported in the United States each year. This malignancy, which accounts for 2% of non-Hodgkin lymphomas, is characterized by lymphoplasmacytic bone marrow infiltration and the presence of serum monoclonal immunoglobulin M (IgM). It is important for health care professionals involved in the care of patients with Waldenström macroglobulinemia to remain up to date in their knowledge of risk stra...

Continue reading

Metastatic Gastric Cancer: Educational Needs

Due to the advances in treatment options for metastatic gastric cancer in recent years, oncology physicians and nurses can individualize treatment selection for patients by considering pathologic and molecular characteristics and emerging efficacy and safety data on novel therapies. Baseline data collected from i3 Health's continuing medical education (CME)/nursing continuing professional development (NCPD)–approved visiting faculty meeting series titled Challenges and Opportunities in Metastati...

Continue reading